Immunization of healthy adult subjects in the United States with inactivated Mycobacterium vaccae administered in a three-dose series.
Heat-killed Mycobacterium vaccae vaccine was administered in a three-dose intradermal schedule to 10 healthy adult volunteers at 0, 2, and 10 months. Local and systemic side effects were monitored and vaccine site reactions were measured and photographed at visits 2 days, 14 days, and 2 months after each dose. Reactions to skin tests with purified protein derivative (PPD) and Mycobacterium avium sensitin (MAS) and titers of antibody to arabinose lipoarabinomannin were determined at baseline and after each dose of vaccine. Lymphocyte proliferation responses to MAS were determined after the final dose of vaccine. Immunization was safe and well tolerated, with maximal induration (range, 6-25 mm) at 2 days. PPD skin test conversions did not occur. Seven subjects completed the three-dose schedule; preexisting immunologic responses to mycobacteria were boosted in three, and a new response was elicited in one. M. vaccae vaccine is safe and induces measurable immunologic responses to mycobacterial antigens in some healthy adults.
von Reyn
C F
CF
Department of Immunology and Microbiology, Dartmouth-Hitchcock Medical Center and Dartmouth Medical School, Lebanon, New Hampshire 03756, USA.
Arbeit
R D
RD
Yeaman
G
G
Waddell
R D
RD
Marsh
B J
BJ
Morin
P
P
Modlin
J F
JF
Remold
H G
HG
D000328:Adult; D000368:Aged; D001428:Bacterial Vaccines / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007114:Immunization; D007115:Immunization Schedule; D007271:Injections, Intradermal; D008297:Male; D008875:Middle Aged; D009161:Mycobacterium / Q000276:immunology*; D009164:Mycobacterium Infections / Q000517:prevention & control*; D012016:Reference Values; D012882:Skin Tests; D014481:United States; D015164:Vaccines, Inactivated / Q000008:administration & dosage
D001428:Bacterial Vaccines; D015164:Vaccines, Inactivated